New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma

Source: OncLive, August 2021

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma, said Daniel Johnson, MD, who added that some of these shifts include a less-toxic frontline regimen to challenge nivolumab (Opdivo) plus ipilimumab (Yervoy), neoadjuvant checkpoint inhibition, and novel strategies for patients with refractory disease who have limited options.

READ THE ORIGINAL FULL ARTICLE